Sélectionner une page
Logo Company

Acticor Biotech

Gilles AVENARD

CEO

Who are we?

ACTICOR BIOTECH, is a French clinical stage bio-pharma company founded late 2013, which develops an innovative treatment for acute ischemic strokes (AIS), representing currently more than 80% of the global stroke market. Despite the clear unmet medical need, no new drug has been approved in the last decade, mainly due to the bleeding risk every new thrombolytic or antiplatelet agent carries. Acticor has developed a new approach targeting the glycoprotein VI, thereby creating a paradigm shift of a new class of antithrombotic drugs without any bleeding risk. ACT-017, Acticor’s lead compound, is a human fragment of Monoclonal Antibody proven to be efficient and very safe in various preclinical models (including primates). It is entering Phase 2a in patients in Q3-2018.